Combination Cancer Therapy for H3 Mutant Tumor Recurrence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies are ineffective against cancers driven by histone H3 mutations, such as pediatric high-grade gliomas, chondroblastomas, and secondary Acute Myeloid Leukemia, and are associated with high recurrence rates and severe side effects, particularly in HRD subtypes of breast, ovarian, prostate, and pancreatic cancers, and melanomas.
Innovation Solution
Administer a combination of drugs from different classes, including PARP inhibitors, DNA-PKcs inhibitors, IDH inhibitors, HDAC inhibitors, POLΘ inhibitors, PDGFR inhibitors, and DNA damaging agents, along with precise radiation delivery to target mutant tumor cells while sparing normal cells, using synergistic effects to minimize doses and prevent recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard dosages of cancer therapies are administered, then therapeutic effectiveness is achieved, but severe systemic side effects occur that negatively affect patient quality of life
Solution Approach 1:
The patent segments the therapeutic approach by combining multiple drugs from different classes (PARP inhibitors, DNA-PKcs inhibitors, IDH inhibitors, HDAC inhibitors, POLΘ inhibitors, PDGFR inhibitors, and DNA damaging agents) to target specific molecular pathways aberrant only in mutant tumor cells. This multi-targeted segmentation allows for lower individual dosages while maintaining overall therapeutic effectiveness, thereby reducing systemic side effects.
Solution Approach 2:
The patent applies local quality by designing a therapy that specifically targets H3 mutant tumor cells through combination drugs that exploit molecular pathways aberrant only in these mutant cells. The synergistic effects of the drug combination enable selective elimination of mutant tumor cells while sparing normal cells carrying wild type H3, thus reducing harmful systemic effects while maintaining local therapeutic effectiveness.
2Reliability
If single drugs are administered to treat H3 mutant cancers, then some therapeutic effect is achieved, but drug resistance develops and recurrence occurs
Solution Approach 1:
The patent segments the DNA repair and tumor cell killing process by targeting multiple pathways simultaneously through combination therapy. By administering drugs from at least two different classes that inhibit complementary DNA repair mechanisms (PARP inhibition, DNA-PKcs inhibition, POLΘ inhibition) and tumor cell proliferation pathways (IDH inhibition, HDAC inhibition, PDGFR inhibition), the treatment prevents any single resistance mechanism from dominating, thereby extending durable remission and preventing recurrence.
Solution Approach 2:
The patent creates a composite therapeutic regimen by combining multiple drugs from different pharmacological classes with synergistic effects. This composite approach targets multiple molecular pathways simultaneously, creating a robust treatment that overcomes drug resistance and prevents cancer recurrence through multi-pathway inhibition rather than single-drug monotherapy.
3Reliability
If high doses of drugs are administered to eliminate tumor cells, then tumor cell elimination is improved, but side effects and toxicity increase
Solution Approach 1:
The patent merges multiple drugs from different classes into a unified combination therapy regimen. By combining PARP inhibitors, DNA-PKcs inhibitors, IDH inhibitors, HDAC inhibitors, POLΘ inhibitors, PDGFR inhibitors, and DNA damaging agents, the treatment achieves synergistic tumor cell elimination at lower individual dosages, thereby reducing drug toxicity while maintaining or improving overall tumor cell elimination effectiveness.
Solution Approach 2:
The patent changes the dosage parameters by administering lower doses of each individual drug in combination rather than high doses of single agents. The synergistic effects of the multi-drug combination allow for reduced individual dosages while achieving equivalent or superior tumor cell elimination, thereby decreasing drug toxicity and side effects.
Data Source
AI summary
The disclosure, in one aspect, relates to methods for treating cancer in a subject, the methods including at least the steps of administering at least one drug from each of at least two classes selected from an inhibitor of poly-ADP ribose polymerase (PARP inhibitor), an inhibitor of DNA-dependent protein kinase catalytic subunit (DNA-PKcs inhibitor), an inhibitor of wild-type isocitrate dehydrogenase (IDH inhibitor), an inhibitor of histone acetyltransferase (HAT inhibitor), an inhibitor of histone deacetylase (HDAC inhibitor), an inhibitor of DNA polymerase Θ (POLΘ inhibitor), an inhibitor of platelet-derived growth factor receptor (PDGFR inhibitor), and a DNA alkylating agent to the subject. In any of these aspects, the disclosed method allows for administering lower doses of the drugs in combination compared to administration as single drugs while preventing the recurrence of the cancer, preventing drug resistance of the cancer, and reducing side effects associated with cancer treatment.